drugset / Trial / NCT01640405

Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells

NCT01640405 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and with three or more circulating tumoral cells.

Timeline

Start
2012-07
Primary completion
2018-11
Completion
2018-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 165 mg/m2 Intravenous
Comparator fluorouracil Small molecule 2400 mg/m2 Intravenous
Comparator fluorouracil Small molecule 3200 mg/m2 Intravenous
Comparator Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Comparator Leucovorin Small molecule 400 mg/m2 Intravenous
Comparator Oxaliplatin Small molecule 85 mg/m2 Intravenous

Indications